SEQIRUS for SEQIRUS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
FY2024 Appropriations and supplemental appropriations, policies related to pandemic preparedness and public health; FY2024 President's Budget proposals, policies related to pandemic preparedness and public health; Department of Defense and Veterans Administration acquisition of influenza vaccine.
Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE FARQUHARSON | — |
Health Issues HCR
Issues related to seasonal and pandemic influenza preparedness; H.R. 5846, Protecting America from Seasonal and Pandemic Influenza Act of 2023; Pandemic and All-Hazards Preparedness Reauthorization; issues related to mRNA technology
Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE FARQUHARSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.